Novel approaches to the development of anti-sepsis drugs

Expert Opin Drug Discov. 2014 May;9(5):523-31. doi: 10.1517/17460441.2014.905538. Epub 2014 Apr 3.


Introduction: Sepsis is the dysregulated systemic immune response to an infection. Experimental and clinical research provided detailed insight into the pathophysiology of the disease, but no pathway explored, so far, has been exploited to deliver effective therapies with regard to significant outcome improvement. Increasing incidence and high mortality of sepsis require novel approaches for the development of anti-sepsis drugs.

Areas covered: Since accurate assessment of the patient's condition in sepsis is the basis for the success of novel anti-sepsis drugs, the authors first review briefly biomarkers for improved diagnostics in sepsis. The authors then discuss specific pharmacological approaches with a focus on immune modulation, for example, Toll-like receptor 4 inhibition and modulation of the endocannabinoid system. The authors also cover iron chelation and uncoupling of the nitric oxide pathway.

Expert opinion: The failure of anti-sepsis treatments in the past is most likely related to wrong timing of the drugs due to missing reliable biomarkers to assess the condition of the patients. The authors believe that the development of anti-sepsis drugs using time-critical ('vertical') and continuous ('horizontal') approaches may provide the answer for future novel therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Biomarkers
  • Humans
  • Immunomodulation / drug effects*
  • Molecular Targeted Therapy
  • Sepsis / drug therapy*
  • Sepsis / immunology
  • Sepsis / metabolism


  • Anti-Inflammatory Agents
  • Biomarkers